JP Morgan Adjusts Alcon Rating to Neutral and Reduces Price Target to $77.53
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 21 2025
0mins
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ALC
Wall Street analysts forecast ALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALC is 91.11 USD with a low forecast of 75.18 USD and a high forecast of 112.77 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
6 Buy
4 Hold
1 Sell
Moderate Buy
Current: 81.150
Low
75.18
Averages
91.11
High
112.77
Current: 81.150
Low
75.18
Averages
91.11
High
112.77
About ALC
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
William Blair Initiates Coverage on Alcon Inc. with Market Perform Rating
- Market Perform Rating: William Blair initiated coverage on Alcon Inc. (NYSE: ALC) with a Market Perform rating on Friday, indicating a neutral outlook on the company's future performance and reflecting a cautious view on its current stock price.
- Growth Drivers: Over the past two years, Alcon has aggressively driven revenue growth through increased R&D spending and several acquisitions, with analysts noting a robust product pipeline despite the stock trading at a roughly 25% premium to historical levels.
- Equipment Market Opportunity: Alcon's equipment segment accounts for about 10% of sales, with the upcoming launches of the UNITY surgical platforms in 2025 and 2026 expected to be significant growth drivers, particularly as customers replace aging systems.
- Consumables Growth Outlook: Consumables are projected to accelerate to about 7% growth in 2026, up from 5% in 2025, primarily driven by the premium-priced UNITY consumables, which enhances Alcon's competitive position in the market.
Continue Reading
Alcon Inc. Completes $750 Million Share Repurchase Program
- Completion of Buyback: Alcon Inc. has successfully completed its $750 million share repurchase program initiated on April 1, 2025, acquiring a total of 9,301,877 shares, which represents 1.9% of the current share capital, thereby enhancing earnings per share and boosting shareholder confidence.
- Significant Buyback Amount: The total buyback volume reached CHF 602 million (approximately $750 million), reflecting the company's recognition of its intrinsic value and aiming to offset the dilutive effects of its equity incentive plans by reducing the number of outstanding shares.
- Enhancing Shareholder Value: The repurchased registered shares will be held in treasury, intended to counteract the dilution caused by equity incentive plans, thereby further enhancing the value and returns for existing shareholders.
- Global Leadership Position: As a global leader in eye care, Alcon serves over 260 million people annually, and the successful execution of this buyback program will further solidify its competitive advantage in the eye care market and drive future business growth.
Continue Reading